$RSPI News
Last published 3mo ago
- 3mo agoRSPIRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested PartiesGlobeNewswireGlen Rock, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to
- 11mo agoRSPIRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested PartiesGlobeNewswireGlen Rock, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (RespireRx or the Company), and its subsidiaries, EndeavourRx LLC (EndeavourRx) and ResolutionRx Ltd (ResolutionRx), collectively, the
- 11mo agoRSPIRespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License AgreementGlobeNewswireGlen Rock, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases
- 11mo agoRSPIRespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private PlacementGlobeNewswireGlen Rock, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases
- 4y agoRSPIRespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of TinnitusGlobeNewswireGlen Rock, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption o
- 4y agoACOGFBABYFEMMAJNHMF+8Life Sciences Companies Investor Presentations Now Available for On-Demand ViewingPR NewswireNEW YORK, Dec. 20, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-de
- 4y agoRSPIRespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™GlobeNewswireGlen Rock, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company"), with a mission to discover and develop innovative and revolutionary treatments to combat diseases caused by disruption of neu
- 4y agoACOGFBABYFEMMAHMTXF+7Life Sciences Virtual Investor Conference: Company Executives Present Live December 16thPR NewswireNEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the
- 4y agoRSPIRespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81GlobeNewswireGlen Rock, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption
- 4y agoRSPIRespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81GlobeNewswireGlen Rock, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption
- 4y agoRSPIRespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord InjuryGlobeNewswireGlen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption
- 4y agoRSPIRespireRx Pharmaceuticals Inc. Announces CEO's OTC Venture Market PodcastGlobeNewswireGlen Rock, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI), ("RespireRx" or the "Company") a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption
- 5y agoRSPIRespireRx Pharmaceuticals Inc. Announces Video Interview of CFOGlobeNewswireGlen Rock, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI), ("RespireRx" or the "Company") a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption
- 5y agoRSPIRespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor ConferenceGlobeNewswireGlen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by dis
- 5y agoRSPIRespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord InjuryGlobeNewswireGlen Rock, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption o
- 5y agoRSPIRespireRx Pharmaceuticals Inc. Provides Update on Its Development ProgramsGlobeNewswireGlen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption